AKT1 and nasopharyngeal carcinoma: In addition, the novel AKT inhibitor, GSK69069, may block the AKT/ZEB1/E-cadherin/vimentin pathway, increase radiosensitivity and prevent recurrence and metastasis following IR therapy in NPC patients.